Physician profile
Jonathan C Hicklin
NPI 1811970478
$1,731.69
in general payments reported to CMS, 2019-2025
26 companies · $23.15 in 2025
The $23.15 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $53.70 · 2021: $433 · 2022: $373 · 2023: $326 · 2024: $268 · 2025: $23.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $340.83 | 2019-2024 | Cequa, Xelpros |
| Abbvie INC. | $175.79 | 2022-2025 | |
| Sight Sciences, INC. | $162.83 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $149.57 | 2019-2023 | Veritas Vision System, Tecnis Iol, Tecnis Simplicity |
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Bausch & Lomb Americas INC. | $87.30 | 2022-2024 | Envista Mx60 Iol, Stellaris, Vyzulta |
| Aerie Pharmaceuticals, INC. | $78.01 | 2019-2021 | |
| Allergan, INC. | $62.35 | 2019-2021 | |
| Biotissue Holdings INC. | $56.90 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.36 | 2019-2021 | |
| Baxter Healthcare | $51.36 | 2022 | |
| Welch Allyn | $51.35 | 2021 | |
| Ocular Therapeutix, INC. | $42.88 | 2019-2024 | Dextenza |
| Alcon Vision LLC | $36.72 | 2019-2022 | |
| Oyster Point Pharma, INC. | $35.13 | 2022-2024 | Ryzumvi, Tyrvaya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $30.01 | 2023 | |
| Mallinckrodt Hospital Products INC. | $30.00 | 2024 | Acthar |
| Optos, INC. | $24.42 | 2019 | |
| Rxsight INC | $23.75 | 2022 | |
| Mallinckrodt Enterprises LLC | $18.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.88 | 2021 | |
| Horizon Therapeutics Plc | $17.27 | 2021 | |
| Maculogix, INC. | $16.49 | 2020 | |
| Ivantis, INC | $15.15 | 2021 | |
| Omeros Corporation | $13.78 | 2019 | |
| Kala Pharmaceuticals, INC. | $11.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hicklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.